Edition:
United Kingdom

Bausch Health Companies Inc (BHC.TO)

BHC.TO on Toronto Stock Exchange

31.09CAD
9:15pm BST
Change (% chg)

$0.58 (+1.90%)
Prev Close
$30.51
Open
$30.74
Day's High
$31.16
Day's Low
$30.63
Volume
381,124
Avg. Vol
746,714
52-wk High
$36.52
52-wk Low
$23.60

Latest Key Developments (Source: Significant Developments)

Bausch Health Announces Pricing Of Private Offering Of Senior Notes
Thursday, 9 May 2019 

May 9 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH ANNOUNCES PRICING OF PRIVATE OFFERING OF SENIOR NOTES.BAUSCH HEALTH COMPANIES INC - PRICED ITS PREVIOUSLY ANNOUNCED OFFERING OF $750 MILLION AGGREGATE PRINCIPAL AMOUNT OF 7.000% SENIOR NOTES DUE 2028.BAUSCH HEALTH COMPANIES INC - PRICED ITS PREVIOUSLY ANNOUNCED OFFERING OF $750 MILLION AGGREGATE PRINCIPAL AMOUNT OF 7.250% SENIOR NOTES DUE 2029.BAUSCH HEALTH COMPANIES INC - 2028 NOTES WILL BE SOLD TO INVESTORS AT A PRICE OF 100.00% OF PRINCIPAL AMOUNT THEREOF.BAUSCH HEALTH COMPANIES INC - 2029 NOTES WILL BE SOLD TO INVESTORS AT A PRICE OF 100.00% OF PRINCIPAL AMOUNT THEREOF.  Full Article

Bausch Health Launches Offering Of $750 Mln Aggregate Principal Amount Of Senior Notes
Thursday, 9 May 2019 

May 9 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH ANNOUNCES LAUNCH OF PRIVATE OFFERING OF SENIOR NOTES.BAUSCH HEALTH COMPANIES INC - HAS LAUNCHED AN OFFERING OF $750 MILLION AGGREGATE PRINCIPAL AMOUNT OF SENIOR NOTES DUE 2028.BAUSCH HEALTH COMPANIES INC - HAS LAUNCHED AN OFFERING ALSO FOR $750 MILLION AGGREGATE PRINCIPAL AMOUNT OF SENIOR NOTES DUE 2029.BAUSCH HEALTH - INTENDS TO USE NET PROCEEDS FROM OFFERING TO REPURCHASE $1,500 MILLION AGGREGATE PRINCIPAL AMOUNT ACROSS CERTAIN OF CO'S SENIOR NOTES.  Full Article

Bausch Health Companies Reports Q1 Loss Per Share Of $0.15
Monday, 6 May 2019 

May 6 (Reuters) - Bausch Health Companies Inc ::ANNOUNCES FIRST-QUARTER 2019 RESULTS AND RAISES FULL-YEAR GUIDANCE.QTRLY REVENUES OF $2.016 BILLION.RAISED FULL-YEAR REVENUES FROM $8.30 - $8.50 BILLION TO RANGE OF $8.35 - $8.55 BILLION.RAISED FULL-YEAR ADJUSTED EBITDA (NON-GAAP)(1) FROM $3.35 - $3.50 BILLION TO RANGE OF $3.40 - $3.55 BILLION.Q1 REVENUE VIEW $2.02 BILLION -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $8.46 BILLION -- REFINITIV IBES DATA.QTRLY LOSS PER SHARE $0.15.BAUSCH + LOMB/INTERNATIONAL SEGMENT REVENUES WERE $1.118 BILLION FOR Q1 OF 2019, AS COMPARED TO $1.103 BILLION FOR Q1 OF 2018.ADJUSTED NET INCOME FOR Q1 OF 2019 WAS $358 MILLION, AS COMPARED TO $312 MILLION.  Full Article

FDA Approves Bausch Health's Duobrii Lotion For Plaque Psoriasis In Adults
Thursday, 25 Apr 2019 

April 25 (Reuters) - Bausch Health Companies Inc ::FDA APPROVES BAUSCH HEALTH'S DUOBRII (HALOBETASOL PROPIONATE AND TAZAROTENE) LOTION 0.01%/0.045% FOR PLAQUE PSORIASIS IN ADULTS.BAUSCH HEALTH COMPANIES INC - DUOBRII IS EXPECTED TO BE AVAILABLE IN JUNE 2019.BAUSCH HEALTH COMPANIES INC - DUOBRII LOTION IS PRICED AT $825 FOR A SUPPLY OF A 100-GRAM TUBE.BAUSCH HEALTH COMPANIES INC - DUOBRII LOTION FOR COMMERCIALLY INSURED PATIENTS WILL HAVE A CO-PAY BETWEEN $25 AND $40.  Full Article

Synergy Pharmaceuticals Confirms Bausch Health As Successful Bidder For Its Business Assets
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - Synergy Pharmaceuticals Inc ::SYNERGY PHARMACEUTICALS CONFIRMS BAUSCH HEALTH AS SUCCESSFUL BIDDER FOR ITS BUSINESS ASSETS.SYNERGY PHARMACEUTICALS - CURRENTLY EXPECTS AGREEMENT WITH BAUSCH HEALTH WILL BE APPROVED BY BANKRUPTCY COURT ON MARCH 1, 2019.  Full Article

Bausch Health Companies Acquires Eton Pharmaceuticals' EM-100 Investigational Eye Drop
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH ACQUIRES ETON PHARMACEUTICALS' EM-100 INVESTIGATIONAL EYE DROP FOR THE TREATMENT OF ITCHY EYES ASSOCIATED WITH ALLERGIES.BAUSCH HEALTH COMPANIES INC - EM-100 HAS BEEN SUBMITTED TO FDA FOR REVIEW.  Full Article

Bausch Health Says Expects To Commence Sales And Marketing Of Vyzulta In Canada In Q2 2019
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH'S CANADIAN BUSINESS POSITIONED FOR GROWTH IN 2019.BAUSCH HEALTH COMPANIES INC - BAUSCH HEALTH EXPECTS TO COMMENCE SALES AND MARKETING OF VYZULTA IN CANADA IN Q2 2019.  Full Article

Bausch+Lomb Announces Health Canada Approval Of Vyzulta For Treatment Of Glaucoma
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Bausch Health Companies Inc ::BAUSCH + LOMB ANNOUNCES HEALTH CANADA APPROVAL OF VYZULTA™ (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION, 0.024%) FOR THE TREATMENT OF GLAUCOMA.BAUSCH HEALTH COMPANIES - ON DECEMBER 27, 2018, HEALTH CANADA ISSUED NOTICE OF COMPLIANCE FOR VYZULTA.  Full Article

Bausch Health To Seek Incremental Amendment To Its Existing Credit Agreement
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH TO SEEK INCREMENTAL AMENDMENT TO ITS EXISTING CREDIT AGREEMENT.BAUSCH HEALTH - UNIT EXPECTED TO BORROW $750 MILLION OF NEW TERM B LOANS UNDER CREDIT AGREEMENT.BAUSCH HEALTH - INTENDS TO HAVE UNIT ISSUE $750 MILLION OF SECURED DEBT SECURITIES.BAUSCH HEALTH - NET PROCEEDS, WITH CASH ON HAND, EXPECTED TO BE USED TO REFINANCE OUTSTANDING 7.500% SENIOR NOTES DUE 2021.  Full Article

Progenics Pharma says Co, Valeant Pharma, Salix Pharma, Wyeth, Actavis Entered Settlement And License Agreement
Thursday, 31 May 2018 

May 31 (Reuters) - Progenics Pharmaceuticals Inc ::PROGENICS PHARMACEUTICALS - ON MAY 25, CO, VALEANT PHARMACEUTICALS, SALIX PHARMACEUTICALS, WYETH, ACTAVIS ENTERED SETTLEMENT AND LICENSE AGREEMENT.PROGENICS PHARMACEUTICALS - THE SETTLEMENT AND LICENSE AGREEMENT IS RELATING TO TWO ACTIONS FOR PATENT INFRINGEMENT IN U.S. DISTRICT COURT -SEC FILING.  Full Article

UPDATE 7-AbbVie looks beyond Humira with $63 bln deal for Botox-maker Allergan

June 25 Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection.